Posted on October 17, 2008 by Sitemaster
I need to state a theoretical conflict of interests up front. I am a member of the Board of Directors of the International Myeloma Foundation. So, having said that …
Fred Baron, a well known Texas-based lawyer and the former finance chairman of John Edwards’s presidential campaign, has progressive multiple myeloma. I am not aware of the [...]
Filed under: Business strategy, Drug approvals and regulation, Health and drug costs | Tagged: Baron, ethics, FDA, myeloma, Tysabri | 1 Comment »
Posted on October 10, 2008 by Sitemaster
So between Bernadine Healy’s recent article in U.S. News and World Report (“Is healthcare Armageddon next?”) and Bob Ehrlich’s response to that article (“The health bubble“) in DTC Perspectives, could it be possible that we are finally deciding to grasp the viscious health care cost nettle that is set to sting us all if we [...]
Filed under: Business strategy, Health and drug costs, health economics | Comments Off
Posted on October 7, 2008 by Sitemaster
A report from London in today’s Daily Telegraph suggests that:
The Government is urging pharmaceutical companies to lower their initial prices for new drugs, with the promise that the [National Health Service] will pay more for them if evidence proves greater effectiveness.
Filed under: Business strategy, Health and drug costs, health economics | Tagged: pharmaceuticals, pricing, UK | Comments Off
Posted on October 7, 2008 by Sitemaster
So you’ll be glad to know it’s not just the health care and the pharmaceutical industries that have some fundamental problems with their communication issues and how these lead to a lousy public image ….
Filed under: Business strategy, Drug approvals and regulation | Tagged: FDA | Comments Off